DexCom, Inc. — News

From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached a key level of support. DXCM recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

zacks.com - 2026-08-03 10:36:04

GRMN, LTH and DXCM tap the health and fitness boom through premium clubs, connected wearables and glucose sensing as wellness demand grows.

zacks.com - 2026-08-03 10:31:25

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

zacks.com - 2026-08-03 10:16:37

Dexcom (DXCM) delivered strong Q2/26 results with 13.1% revenue growth, 49.7% operating income growth, and raised FY26 guidance. DXCM's growth drivers include G7 system adoption, international expansion, and initiatives like 'Road to 100' targeting broader diabetes coverage. Margin improvements, ongoing share buybacks, and a robust balance sheet support DXCM's growth and capital allocation strategy.

seekingalpha.com - 2026-08-03 07:16:30

DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.

zacks.com - 2026-07-31 14:42:03

Revenue: Worldwide revenue of $1.31 billion, up 13% reported and 12% organic year-over-year.US Revenue: $933 million, up 11% year-over-year.International Revenu

gurufocus.com - 2026-07-31 00:04:00

DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-30 22:03:14

DexCom NASDAQ: DXCM reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets.

marketbeat.com - 2026-07-30 19:04:40

DexCom (DXCM) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.48 per share a year ago.

zacks.com - 2026-07-30 18:26:05

Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates ​on Thursday, banking on sustained demand for its ‌continuous glucose monitors that track blood sugar levels, sending shares of the company up ​over 4% in extended trading.

reuters.com - 2026-07-30 16:32:51

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.

businesswire.com - 2026-07-30 16:02:00

They may profit from the rapidly growing GLP-1 market in very different ways.

fool.com - 2026-07-29 16:34:00

Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.

zacks.com - 2026-07-29 11:56:11

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com - 2026-07-29 09:12:00

Dimensional Fund Advisors LP boosted its stake in DexCom, Inc. (NASDAQ: DXCM) by 1.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,895,549 shares of the medical device company's stock after purchasing an additional 23,844 shares during the

defenseworld.net - 2026-07-29 03:39:40

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-07-28 10:46:10

DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.

zacks.com - 2026-07-27 10:06:31

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-23 11:01:15

Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors

gurufocus.com - 2026-07-23 08:00:00

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th.

businesswire.com - 2026-07-23 07:00:00

Alamar Capital Management LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,605 shares of the medical device company's stock, valued at approximately $854,000. A number of other institutional

defenseworld.net - 2026-07-23 03:58:03

SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom.

businesswire.com - 2026-07-22 17:15:00

Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

zacks.com - 2026-07-21 10:41:07

DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with diabetes.

zacks.com - 2026-07-14 11:21:37

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi.

businesswire.com - 2026-07-13 16:45:00

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July

gurufocus.com - 2026-07-09 09:00:00

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

businesswire.com - 2026-07-09 08:30:00

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-07-08 10:45:26

DexCom, Inc.  DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further.

zacks.com - 2026-07-06 15:36:19

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com - 2026-07-03 12:27:00

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.

seekingalpha.com - 2026-07-02 02:10:16

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.

zacks.com - 2026-06-26 09:36:09

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.

zacks.com - 2026-06-24 10:31:17

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h.

businesswire.com - 2026-06-23 09:00:00

The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo Nordisk NYSE: NVO or Eli Lilly NYSE: LLY, the leading companies responsible for developing and manufacturing products like Ozempic and Zepbound.

marketbeat.com - 2026-06-20 08:45:12

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

barrons.com - 2026-06-18 14:14:00

Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks stocks have lagged much of the broader market this year.

marketbeat.com - 2026-06-18 09:31:18

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.

zacks.com - 2026-06-16 10:56:14

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-16 10:46:09

The U.S. Food and Drug Administration said on Friday it has expanded the ​use of Dexcom's Stelo Glucose Biosensor ‌System to children with diabetes, making it the first over-the-counter continuous glucose monitor for pediatric use.

reuters.com - 2026-06-12 16:15:32

Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors ​it bought from licensed distributors had been ‌slated for destruction, after the device maker warned some units were stolen during disposal and ​resold.

reuters.com - 2026-06-11 06:08:12

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-10 10:51:07

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

zacks.com - 2026-06-08 14:31:04

DexCom Inc. (NASDAQ:DXCM) stock is trading higher on Monday after the diabetes management company reported positive results from its CONNECT randomized controlled trial.

benzinga.com - 2026-06-08 14:15:02

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clini

gurufocus.com - 2026-06-06 15:00:00

Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type ​2 diabetes not using insulin, compared with routine care, according to ‌study results.

reuters.com - 2026-06-06 14:49:45

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of.

businesswire.com - 2026-06-06 14:45:00

Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.

investorplace.com - 2026-06-05 00:00:00

DXCM banks on CGM market growth, expanding international demand and strong Q1 momentum, though competitive pressures remain a key risk.

zacks.com - 2026-06-04 15:10:14